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Possible Role of Apoptosis in the Pathogenesis of
Bleomycin-Induced Scleroderma
Toshiyuki Yamamoto and Kiyoshi Nishioka
Tokyo Medical and Dental University School of Medicine, Department of Dermatology, Tokyo, Japan
To elucidate the role of apoptosis in cutaneous sclerosis, we examined the induction of apoptosis and expression
of Fas, Fas ligand, as well as caspase-3 in a murine model of bleomycin-induced scleroderma. Dermal sclerosis was
induced by local injections of bleomycin (1 mg per mL) in C3H/HeJ mice. Induction of apoptosis was examined by
TUNEL (terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end-labeling) assay and
DNA gel electrophoresis. TUNEL positivity was prominently detected on keratinocytes and inﬁltrating mononuclear
cells, but not endothelial cells and ﬁbroblasts, in the lesional skin. DNA fragmentation revealed laddering at 3 to 4
wk following bleomycin treatment. Immunohistochemistry showed increased expression of Fas in inﬁltrating
mononuclear cells at early phases following bleomycin exposure, whereas constitutive expression in ﬁbroblasts.
Fas ligand expression was increased in mononuclear cells as well as ﬁbroblasts in the sclerotic skin. Results of
reverse transcription–polymerase chain reaction analysis revealed that expression of Fas ligand mRNA was
upregulated and reached a maximum at 3 wk, whereas Fas mRNA was continuously detected. mRNA expression as
well as activity of caspase-3 was also enhanced at 3 wk. Administration of neutralizing anti-Fas ligand antibody
together with local bleomycin treatment reduced the development of dermal sclerosis, associated with the
reduction of TUNEL-positive mononuclear cells and also with the blockade of apoptosis. Caspase-3 activity in the
lesional skin was also signiﬁcantly reduced after anti-Fas ligand treatment. These ﬁndings suggest that excessive
apoptosis, which is mediated by Fas/Fas ligand pathway and caspase-3 activation, is involved in the pathogenesis
of bleomycin-induced scleroderma, possibly by playing an inﬂammatory role.
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Systemic sclerosis is a connective tissue disorder char-
acterized by excessive production and accumulation of
extracellular matrix proteins in the affected skin, as well as
various internal organs (Krieg and Meurer, 1988; LeRoy et al,
1991). In particular, type I, III collagen, fibronectin, and
proteoglycans are produced by activated fibroblasts in the
affected sites. Interactions among lymphoid cells, endothe-
lial cells, and fibroblasts are likely to be central to the
pathogenesis of systemic sclerosis; however, its etiology
has not been fully elucidated as yet.
Recent studies suggest the involvement of apoptosis in
several autoimmune disorders (Vaishnaw et al, 1997;
Grodzicky and Elkon, 2000; Ricci-Vitiani et al, 2000).
Apoptotic process is suggested to be involved in the
pathogenesis of systemic sclerosis (Jelaska and Korn,
2000; Santiago et al, 2001). Apoptosis is a process
regulated by numerous genes and factors. One possible
mechanism is induction of apoptosis via death receptors
such as CD95 (APO-1/Fas). Fas is a 45 kDa cell-surface
receptor of the tumor necrosis factor/nerve growth factor
receptor family. Fas is highly expressed in activated
lymphocytes and in a variety of cells of lymphoid or
nonlymphoid origin, as well as tissues and tumor cells (Itoh
et al, 1991; Nagata and Golstein, 1995; Walczak and
Krammer, 2000). Fas ligand (FasL) is a membrane protein
belonging to the tumor necrosis factor family. Although
expression of FasL was originally thought to be restricted to
activated T cells and natural killer cells, FasL is also
expressed in immune privileged sites (Suda et al, 1993;
Nagata, 1996; Griffith and Ferguson, 1997). Fas and FasL
are widely expressed and function in many tissues. When
FasL binds to Fas on Fas-sensitive target cells, target cells
die by apoptosis, triggering a cascade of caspases. The
Fas/FasL system is a key molecular regulator of apoptosis
and is also involved in the pathogenesis of various diseases
(Fadeel et al, 1999; Siegel and Fleisher, 1999). Caspases are
suggested to play an essential part in both the regulation
and execution phases of apoptotic cell death and act
upstream of DNA fragmentation (Los et al, 1995; Thornberry
et al, 1997). Caspase-3 is considered to be key executor of
apoptosis and is activated via the mitochondrial, death
receptor such as Fas/FasL and tumor necrosis factor/tumor
necrosis factor receptor, or endoplasmic reticulum routes.
We previously established a mouse model for scleroder-
ma by the treatment with bleomycin (Yamamoto et al,
1999a,b, 2000; Yamamoto and Nishioka, 2001; Yamamoto
and Nishioka, 2002). Repeated local injections of bleomycin
induce dermal sclerosis that resemble human scleroderma
both histologically and biochemically. Bleomycin is known
to induce apoptosis in vitro (Omar et al, 1993; Hamilton et al,
1995; Ortiz et al, 1998). In this study, we examined the
involvement of apoptosis as well as Fas and FasL system in
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this in vivo model for scleroderma. Caspase-3 expression
and activity was also examined following bleomycin
exposure. We further investigated whether inhibition of
FasL can suppress the induction of dermal sclerosis
induced by bleomycin.
Results
Detection of apoptosis in the lesional skin following
bleomycin treatment At first, bleomycin-treated skin was
examined for the presence of TUNEL-positive cells. In situ
detection of cell death by TUNEL assay showed only faint
apoptotic signals on the hair follicles in the PBS-treated skin
(Fig 1A). By contrast, positive signals for TUNEL were
detected on the infiltrating mononuclear cells, hair follicles,
and sebaceous glands in the dermis, and also a few
positively labeled few keratinocytes were scattered follow-
ing bleomycin treatment as early as at 1 wk (Fig 1B). The
number of TUNEL-positive infiltrating cells were markedly
increased at 3 wk following bleomycin exposure (Fig 1C),
associated with bleomycin-induced inflammatory infiltrates
in the skin. Also, positively labeled keratinocytes were
prominently detected at 3 wk (Fig 1D). Negative controls
without TdT did not show nuclear labeling (Fig 1E). On the
contrary, positive labeling was not detected on the
endothelial cells (Fig 1F), and positively labeled fibroblastic
cells were few in the lesional skin after bleomycin treatment.
Results of gel electrophoresis of DNA extracted from skin
tissues showed ladder patterns of DNA cleavage, confirm-
ing the development of apoptosis. DNA fragmentation in the
lesional skin was prominently detected at 3 and 4 wk
following bleomycin treatment (Fig 2). Here, we have
demonstrated in vivo data that apoptosis was induced in
the lesional skin following bleomycin treatment by a
combination of TUNEL and gel electrophoretic analysis.
Expression of Fas and FasL in the lesional skin of
bleomycin-induced scleroderma Fas/FasL system is a
key molecular regulator of apoptosis. To address the
potential involvement of Fas/FasL pathway in the patho-
genesis of bleomycin-induced scleroderma, we examined
the expression of these molecules. Immunohistochemical
localization revealed that weak expression of Fas was
detected in hair follicles, sebaceous glands, and epidermis
in the PBS-treated skin (Fig 3A). On the other hand, Fas was
detected on the cell membranes of some mononuclear cells
in the dermis at 1 wk following bleomycin treatment, and the
positive signals for Fas on the infiltrating mononuclear cells
were highest at 2 wk (Fig 3B). Fas was also expressed on
fibroblastic cells constitutively during 1 to 4 wk after
bleomycin exposure (Fig 3C). FasL was not detected in
the PBS-treated skin (Fig 3D), whereas positive on the
inflammatory cells as early as at 1 wk after bleomycin
treatment (Fig 3E). Furthermore, FasL was also detected on
fibroblastic cells at 3 to 4 wk (Fig 3F). Negative controls for
Fas and FasL are shown in Fig 3(G) and Fig 3(H),
respectively. Reverse transcription–PCR analysis showed
that Fas mRNA was clearly detectable in all tissues during
1 to 4 wk following bleomycin treatment, whereas faintly
detected in the PBS-treated skin (Fig 3I). FasL mRNA
expression was upregulated and peaked at 3 wk following
bleomycin treatment (Fig 3I). Quantification of the signal
indicated up to a 7.5-fold increase of FasL mRNA, as
compared with the level detected in the PBS-treated skin.
Expression and activity of caspase-3 in the lesional skin
of bleomycin-induced scleroderma As caspase-3 is
believed to be one of the most commonly involved in the
execution of apoptosis in various cell types, and the Fas/
FasL pathway is an upstream signal for caspase-3 activa-
tion, we examined the expression and activity of caspase-3.
Figure 1
TUNEL staining of the lesional skin.
Positive signals were faintly detected in
the hair follicles in the PBS-treated skin
(A). TUNEL-positive cells were detect-
able on the cellular infiltrates in the
dermis at 1 wk after bleomycin treatment
(B), and further increased at 3 wk (C).
TUNEL-positive cells were also promi-
nently detected on keratinocytes (D). No
positive signals were observed in nega-
tive controls without TdT (E). On the
contrary, TUNEL was negative on the
endothelial cells even in the sclerotic
skin, although positive on perivascular
mononuclear cells (F). Original magnifi-
cation: (A,B)  100; (C)  200;
(D)  300; (E)  120; (F)  400. Scale
bars: (A,B) 100 mm; (C) 50 mm; (D) 33
mm; (E) 83 mm; (F) 25 mm.
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Results of immunohistochemistry showed that caspase-3
expression was detected in the epidermis, hair follicles, and
sebaceous glands, but not detected on cellular infiltrates
scattered in the PBS-treated skin (Fig 4A). On the contrary,
mononuclear cells infiltrating in the lower dermis were
positive for caspase-3 after bleomycin exposure, in which
immunoreactivity was detected in both the nucleus and the
cytoplasm (Fig 4B,C). A small number of fibroblastic cells
were also detectable. Reverse transcription–PCR analysis
showed that caspase-1 and caspase-3 mRNA were con-
currently upregulated in the lesional skin of the bleomycin-
treated mice, compared with those of the PBS-treated mice
(Fig 4D). Both caspase-1 and caspase-3 mRNA levels
peaked at 3 wk following bleomycin treatment. Colorimetric
enzymatic assay showed a 2-fold increase in the caspase-3
activity in the bleomycin-treated skin, as compared with the
PBS-treated skin (Fig 4E). Caspase-3 expression and
activity were correlated with an increased level of FasL,
an upstream signals for caspase-3 activation.
Blockade of dermal sclerosis by anti-FasL Finally, to
determine whether neutralization of FasL can suppress the
induction of dermal sclerosis, we examined the effect of
neutralizing antibody against FasL on the development of
bleomycin-induced scleroderma. Mice were subcuta-
neously injected with bleomycin and intravenously treated
with neutralizing anti-FasL antibody MFL3 every other day
for 4 wk. Mice treated with bleomycin and normal hamster
IgG showed definite dermal sclerosis with thickened
collagen bundles and deposition of homogeneous materials
in the thickened dermis (Fig 5A). On the contrary, treatment
with anti-FasL antibody partially prevented the development
of dermal sclerosis, as compared with mice treated with
normal hamster IgG (Fig 5B). Collagen content in the skin
was significantly reduced up to 50% after treatment with
anti-FasL antibody (140.6  8.5% of control), as compared
with mice treated with normal hamster IgG (181.4  6.1% of
control) (po0.01) (Fig 5C). In mice treated with PBS,
collagen content in the skin was not altered following anti-
FasL treatment (not shown). Neutralizing anti-FasL antibody
significantly decreased the number of TUNEL-positive
mononuclear cells in the sclerotic skin (Fig 5D), as well as
Figure 2
Electrophoretic analysis of DNA extracted from the lesional skin
after either PBS or bleomycin treatment. Marker (M) and control (C)
skin treated with PBS for 4 wk. Lane 1: 1 wk after bleomycin treatment.
Lane 2: 2 wk after bleomycin treatment. Lane 3: 3 wk after bleomycin
treatment. Lane 4: 4 wk after bleomycin treatment. Results shown are
representative of three independent experiments.
Figure3
Expression of Fas and FasL in the
lesional skin by immunohistochemis-
try (A–H) and reverse transcription–
PCR (I). Fas was faintly detected on the
hair follicles, sebaceous glands, and
epidermis in the PBS-treated skin (A).
After exposure with bleomycin (BLM),
Fas was detected on the cellular infil-
trates (B) as well as fibroblasts (C) in the
dermis (B; at 2 wk and C; at 3 wk). FasL
was negative in the PBS-treated skin (D).
On the contrary, FasL was detectable on
the cellular infiltrates as early as at 1 wk
after bleomycin treatment (E), and also
expressed on fibroblasts at 4 wk (F).
Negative controls for Fas (G) and FasL
(H) are shown. Original magnification:
(A,D)  200; (B,C,E–H)  400. Scale
bars: (A,D) 50 mm; (B,C,E–H) 25 mm. (I)
Expression of Fas and FasL mRNA in
skin tissues. Total RNA was extracted
from skin samples treated with either
PBS for 4 wk (Cont) or bleomycin for 1 to
4 wk, and analyzed by reverse transcrip-
tion–PCR with specific primers. Results
shown are representative of three inde-
pendent experiments.
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dramatically suppressed the apoptotic condition indicated
by DNA fragmentation (Fig 5E). Moreover, neutralization of
FasL suppressed caspase-3 activation in the lesional skin
(Fig 5F), suggesting a relationship between Fas/FasL
system and caspase-3 activation-mediated apoptosis.
Discussion
In this study, we first demonstrate that apoptosis is induced
in the lesional skin following local bleomycin treatments by
TUNEL assay and DNA gel electrophoretic analysis.
Apoptosis was clearly detected at later stages, and TUNEL
reactive cells were mainly infiltrating mononuclear cells and
also keratinocytes in the bleomycin-treated skin. Recent
studies suggest that endothelial cell apoptosis is an early
event in the pathogenesis of scleroderma. Endothelial cell
apoptosis was first noted in the UCD 200/206 chickens that
develop hereditary systemic connective tissue disease
resembling human systemic sclerosis (Sgonc et al, 1996).
This phenomenon is observed before perivascular mono-
nuclear cell infiltration occurs. Also, TUNEL was shown to
be positive on the endothelial cells in human scleroderma
skin (Santiago et al, 2001). On the contrary, not only in Tsk 1
but also in Tsk 2 mice, alterations in endothelial apoptosis
induction were not involved in the disease development
(Sgonc et al, 1999). Thus, the mechanism and significance
of endothelial cell apoptosis in scleroderma is still uncertain.
Our results showed no TUNEL labeling on endothelial cells,
but was positive in cellular infiltrates around the vessels,
suggesting that endothelial apoptosis is not involved in the
pathogenesis of bleomycin-induced scleroderma.
Transforming growth factor-b plays a crucial part in
scleroderma, and also in this murine model (Yamamoto
et al, 1999a,c). In addition to the variety of functions of
transforming growth factor-b, including the chemotactic
attraction of macrophages and fibroblasts, the stimulation
of fibroblast proliferation and production of extracellular
matrix proteins, the downregulation of extracellular matrix
proteinases, and complementary upregulation of proteinase
inhibitors, transforming growth factor-b protects myofibro-
blasts against apoptotic stimuli (Arora and McCulloch,
1999; Zhang and Phan, 1999). Scleroderma fibroblasts
derived from affected dermis, which had a higher ratio of
a-smooth muscle actin-positive cells, are shown to be
resistant to anti-Fas-induced apoptosis (Jelaska and Korn,
2000). We have recently reported the phenotypic changes
of sclerotic fibroblasts into a-smooth muscle actin-positive
myofibroblasts in the lesional skin in this model (Yamamoto
and Nishioka, 2002). Our results in this study showed that
TUNEL-positive cells were mainly mononuclear cells and
keratinocytes, and there was little or no TUNEL positivity on
fibroblasts in the lesional skin following bleomycin treat-
ment. Thus, sclerotic fibroblasts are suggested to be
resistant to bleomycin-induced apoptosis.
Fas/FasL system is a key molecular regulator of
apoptosis. In this model, immunohistologic examination
showed that Fas as well as FasL was strongly expressed in
the infiltrating inflammatory cells and fibroblastic cells after
bleomycin treatments. The overlapping expression of Fas
and FasL during bleomycin treatment was accompanied by
apoptosis in the lesional skin. Fas signaling is suggested to
be proinflammatory, because it results in activation of
caspases, which cleaves and activates the proinflammatory
cytokines (Restifo, 2000). Also, it is shown that FasL
expression links with inflammation, and in vivo studies
show that membrane-bound FasL effectively induces an
inflammatory response (Hohlbaum et al, 2000). Although
FasL is expressed mainly in active T lymphocytes, FasL ex-
pression can be induced in nonlymphoid tissues (Bonfoco
Figure 4
Expression and activity of caspase-3.
Immunohistologic expression of cas-
pase-3 in the lesional skin following
PBS or bleomycin treatment. Immunor-
eactivity for caspase-3 is not detected
on the scattered cellular infiltrates in the
PBS-treated skin (A), whereas detected
on the infiltrating mononuclear cells in
the bleomycin-treated skin at 3 wk (B,C).
(D) Representative results of reverse
transcription–PCR analysis for caspase-
1 and caspase-3 mRNA levels in the skin
following either bleomycin (1–4 wk) or
PBS (3 wk) (Cont) treatment. (E) Colori-
metric assay of caspase-3 activity in the
mice skin treated with either bleomycin
or PBS for 3 wk. Original magnification:
(A)  200; (B)  100; (C)  400. Scale
bars: (A) 50 mm; (B) 100 mm; (C) 25 mm.
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et al, 1998), and is shown in dermal fibroblasts following
activation (Saitoh et al, 2000) or renal fibroblasts (Ortiz et al,
1997). Our data suggest that dermal fibroblasts can be one
of the sources of FasL. Induction of FasL on dermal
fibroblasts may be upregulated by proinflammatory or
fibrogenic cytokines in the lesional skin.
At present, the precise role of apoptosis in the develop-
ment of bleomycin-induced dermal sclerosis is unclear. As
apoptosis plays an important part in the normal resolution
process, its alteration may result in pathologic conditions. It
is speculated that at sufficiently high levels of apoptosis, the
skin clearance system may be impaired or overwhelmed by
the need to remove apoptotic cells. This disturbance of the
resolution of the inflammation may develop secondary
necrosis of apoptotic cells, which induce skin tissue
damage by releasing proinflammatory cytokines and cyto-
toxic contents, leading to a fibroproliferative response.
Systemic administration of neutralizing anti-FasL antibody
suppressed the induction of dermal sclerosis, in association
with a significant reduction of the number of TUNEL-positive
mononuclear cells as well as inhibition of DNA fragmentation
in the skin. These effects of anti-FasL antibody are
considered to be specific, because treatment with normal
hamster IgG had no effect. Furthermore, caspase-3 activity
was also significantly suppressed, indicating that caspase-3
is the key mediator of bleomycin-induced apoptosis in the
skin. A recent report demonstrated that injection of anti-FasL
antibody ameliorated the development of bleomycin-in-
duced pulmonary fibrosis (Kuwano et al, 1999). They
suggested that the inhibition of apoptosis induced by the
Fas/FasL pathway may be of primary importance in
preventing pulmonary fibrosis induced by bleomycin. On
the other hand, as anti-FasL antibody could not provide
complete protection against the induction of dermal sclero-
sis, other pathways are also supposed to activate mechan-
isms of the development of dermal sclerosis.
In conclusion, this study demonstrates an excessive
apoptosis of mononuclear cells infiltrating in the bleomycin-
Figure 5
Effect of neutralizing anti-FasL antibody. (A,B) Histology of the lesional skin (hematoxylin and eosin stain). Mice were treated with bleomycin
(BLM) 1 mg per mL together with intravenous administration of either anti-FasL antibody or control normal hamster IgG. Mice treated with bleomycin
and normal hamster IgG for 4 wk demonstrate definite dermal sclerosis with thickened collagen bundles (A). Mice treated with bleomycin and anti-
FasL neutralizing antibody for 4 wk show reduction of dermal sclerosis (B). Original magnification:  100. Scale bar: 100 mm. (C) Collagen content
in the skin. Collagen content was significantly suppressed in mice treated with intravenous administration of anti-FasL antibody together with local
bleomycin, compared with those treated with control normal hamster IgG and bleomycin. Data represent the mean  SD of six mice (po0.01). (D)
Morphometric analysis of the number of TUNEL-positive cells per high-power field (HPF) in microscopy. The number of TUNEL-positive
mononuclear cells was significantly decreased in the skin of mice treated with anti-FasL neutralizing antibody compared with that in mice treated
with control normal hamster IgG, together with local bleomycin treatment. (E) Electrophoretic analysis. DNA fragmentation was clearly detected in
DNA extracted from the skin treated with bleomycin and normal hamster IgG for 4 wk (lane 1), which diminished in DNA extracted from the skin
treated with bleomycin and anti-FasL antibody (lane 2). Results shown are representative of three independent experiments. (F) Suppression of
caspase-3 activity. Intravenous injections of FasL antibody together with local bleomycin treatment for 4 wk significantly inhibited the caspase-3
activity, compared with mice treated with normal hamster IgG and bleomycin.
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treated skin, which may induce an inflammatory process
and then lead to fibrosis, suggesting a pivotal role of Fas/
FasL signaling and furthermore Fas/FasL-mediated cas-
pase-3 activation in the pathogenesis of bleomycin-induced
scleroderma. The continuous and extensive expression of
FasL may participate in the development of cutaneous
fibrosis/sclerosis by inducing excessive apoptosis or by
modulating inflammatory mediators.
Materials and Methods
Mice Specific pathogen-free, female C3H/HeJ mice (6 wk old)
were purchased from Sankyo Labo Service Co. (Tokyo, Japan),
and kept under standard conditions with food and water ad libitum.
Mice were handled in accordance with institutional animal care and
use committee protocols approved by the animal facility of Tokyo
Medical and Dental University.
Development of dermal sclerosis by bleomycin Dermal sclero-
sis was induced by local injections of bleomycin (Nippon Kayaku
Co., Tokyo), which was dissolved in phosphate-buffered saline
(PBS) and sterilized by filtration (0.2 mm). One hundred microliters
of bleomycin (1 mg per mL) was subcutaneously administered into
the shaved back skins every other day for 4 wk.
Immunohistochemical analysis Immunohistochemical examina-
tion was performed with avidin–biotin peroxidase technique using
5 mm thick cryostat sections prepared on poly L-lysin coated
slides. The sections were incubated with primary monoclonal
antibodies against Fas (Jo2), FasL (MFL3) (both purchased from
BD Pharmingen, San Diego, California) and polyclonal antibody
against caspase-3 (L-18) (purchased from Santa Cruz Biotechnol-
ogy Inc., Santa Cruz, California) (1:250, diluted in PBS) for 2 h at
room temperature, followed by incubation with biotin-conjugated
secondary antibodies. The sections were developed with 3,30-
diaminobenzidine solution as chromogen, counterstained with
hematoxylin, dehydrated, cleared, and mounted. Negative controls
were prepared by omission of the primary antibodies and by the
substitution with control IgG.
Reverse transcriptase–polymerase chain reaction (reverse
transcriptase–PCR) analysis Total RNA was isolated from
biopsied skins using RNeasy kit (Qiagen, Tokyo, Japan). Com-
plementary single-stranded DNA was synthesized from total RNA
by reverse transcription as described previously (Yamomoto et al,
1999a). The cDNA was amplified by PCR using Ready-to-Go PCR
beads (Amersham Pharmacia Biotech, Piscataway, New Jersey)
with specific primers for Fas (upstream; 50-GAGAATTGCTGAAGA-
CATGACAATCC-30, downstream; 50-GTAGTTTTCACTCCAGACAT-
TGTCC-30), FasL (upstream; 50-AAGCTTCAGCTCTTCCACCTG-
30, downstream; 50-ATGAATTCCTGGTGCCCATG-30), caspase-1
(upstream; 50-GGGACCTATGTGATCATGTCTC-30, downstream;
50-CAGTCAGTCCTGGAAATGTGCC-30), caspase-3 (upstream;
50-CTGACTGGAAAGC-CGAAA-30, downstream; 50-GCAAAGGGA-
CTGGATGAA-30), and GAPDH (upstream; 50-TGAAGGTCGGTGT-
GAACGGATTTGGC-30, downstream; 50- CATGTAGGCCATGAGGT-
CCACCAC-30). The PCR conditions were consisted of denaturation
at 941C for 1 min, annealing at 551C for 30 s, and elongation at
721C for 30 s, for a total of 25 cycles (for GAPDH), and 30 cycles
(for otherwise). Cycle curve studies confirmed that amplification
occurred in a linear range. After amplification, PCR products were
subjected to electrophoresis on 1.7% agarose gels and detected
by ethidium bromide under ultraviolet illuminator. For negative
control, total cellular RNA without reverse transcription was used.
Terminal deoxynucleotidyl transferase (TdT)-mediated dUTP-
biotin nick end-labeling (TUNEL) staining To detect DNA strand
breaks, which are associated with the apoptotic response, an
in situ cell death detection kit (Roche Diagnostics GmbH
Maanheim, Germany) was used using cryostat sections, based
on the TUNEL assay. Negative controls were obtained without TdT.
DNA fragmentation by agarose gel analysis Skin samples were
cut into small pieces by scissors in sample buffer, and DNA was
extracted using the apoptosis ladder kit (Roche Diagnostics
GmbH). DNA samples were loaded on a 1% agarose gel containing
ethidium bromide and visualized under ultraviolet light.
Activity of caspase-3 The level of caspase-3 activity was
determined using a commercial assay kit (Caspase Colorimetric
Protease assay kit; MBL, Nagoya, Japan). The skin extracts were
prepared by homogenization of skin tissues in a lysis buffer.
Homogenates were centrifuged at 7,000 g for 10 min, and the
supernatants were assayed. Caspase-3 activity was measured by
cleavage of the fluorogenic substrates DEVD-pNA. Fifty microliters
of 2  reaction buffer with 10 mmol per liter dithiothreitol and 5 mL
of 4 mmol per liter DEVD-pNA substrate were added to 50 mL of
supernatants containing a total of 50 mg of extracted proteins,
followed by 1 h of incubation in a water bath at 371C. Optical
density for each specimen was determined at 405 nm using a plate
reader.
Administration of anti-FasL To examine whether blockade of
FasL leads to prevention of dermal sclerosis, 5 mL of anti-FasL
antibody MFL3 (BD Pharmingen) (0.2 mg per mL) or normal
hamster IgG were injected via the tail vein every other day for 4 wk
together with local bleomycin (1 mg per mL) treatment.
Collagen content For collagen assay, 8 mm punch biopsy
specimens were excised from the shaved back skins, and stored
at 801C. Collagen deposition was estimated using the Sircol
Collagen Assay kit (Biocolor, Belfast, Northern Ireland). The
biopsies were homogenized in 0.5 M acetic acid, and 1 mL of
Sircol dye reagent that binds to collagen was added to each
sample and then mixed for 30 min. After centrifugation, the pellet
was suspended in 1 mL of the alkali reagent included in the kit and
assessed colorimetrically at 540 nm by a spectrophotometer.
Collagen standard solutions were utilized to construct a standard
curve. Results were expressed as a percentage compared with
mice that received only PBS injections.
Statistical analysis In each experiment, six mice were examined.
Results were expressed as mean  SD. Significance testing was
analyzed using Mann–Whitney U test. A p value less than 0.05 was
considered to be significant.
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